{"id":249726,"date":"2023-12-07T00:00:00","date_gmt":"2023-12-07T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0011-2023-biopharma-biosimilars-current-treatment-biosimilar\/"},"modified":"2026-04-17T11:23:04","modified_gmt":"2026-04-17T11:23:04","slug":"biosbi0011-2023-biopharma-biosimilars-current-treatment-biosimilar-target-product-profiles-immunology","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0011-2023-biopharma-biosimilars-current-treatment-biosimilar-target-product-profiles-immunology\/","title":{"rendered":"Biosimilars – Current Treatment – Biosimilar Target Product Profiles (Immunology)"},"content":{"rendered":"

To obtain a competitive edge in an ever-growing market, biosimilar manufacturers have been using lower prices in reference to branded products and other biosimilars as a primary strategy to improve the attractiveness of their products. In this scenario, we examine the influence of different list price levels on prescription likelihood and preference shares when choosing biosimilars within the same class. TPP<\/abbr> A models a biosimilar agent at the same list price as the brand, TPP<\/abbr> B models a biosimilar at a list price 20% lower than the brand, and TPP<\/abbr> C models a biosimilar at a list price 50% lower than the brand. All other attributes are set as equal (original profile).<\/p>\n

Under these conditions, TPP C received higher preference shares along with a higher likelihood to be prescribed by rheumatologists, whereas TPP A had lower preference shares and likelihood to be prescribed. When the list price of TPP A is 30% lower than that of the brand, its preference shares and prescription likelihood increase, but it still garners lower shares compared with TPP C (list price 50% lower than the brand) (data not shown). These findings suggest that biosimilars with lower list prices have an opportunity for higher uptake among physicians compared with those with list prices the same as or closer to the brand.<\/p>\n

Apart from list price levels, the duration a biosimilar has been on the market has an impact on the preference shares and likelihood of prescription. A change in only the postmarketing data (time on the market) to 12 months or 24 months for TPP A while maintaining the original profiles for TPP B and TPP C improved its preference shares compared with TPP B across the United States and Europe. However, TPP C was still observed to maintain higher preference shares and showed higher likelihoods of prescription among surveyed rheumatologists in both the United States and Europe.\u00a0<\/p>\n

Although type of manufacturer is the fourth most important attribute, at different price levels the type of manufacturer is less impactful in influencing preference shares and likelihood to prescribe. When changing only the type of manufacturer to a biotech company from outside the United States or Europe or to a nonpharma partnered with a pharma company for TPP B and TPP C while keeping the original profile for TPP A, TPP C still maintained the highest preference shares and likelihood to prescribe, while TPP A had the lowest preference shares and likelihood to prescribe across the United States and Europe.<\/p>\n

To summarize, the TPP scenario results suggest that although biosimilars that have been in the market for a longer duration have an advantage over their competitors, pricing remains the primary differentiating factor driving market uptake of biosimilars.<\/p>\n","protected":false},"template":"","class_list":["post-249726","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-biosimilars","biopharma-product-current-treatment","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249726","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249726\/revisions"}],"predecessor-version":[{"id":578794,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249726\/revisions\/578794"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249726"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}